Özyürek, H.Uyan, A.P.Keskin, MusaAfşar, Y.Kocabay, Kenan2020-04-302020-04-3020020010-0161https://hdl.handle.net/20.500.12684/184Bronchiolitis is an acute inflammatory respiratory illness of children less than two years of age. Therapies used in the treatment of bronchiolitis include adequate hydration, supplementary oxygen, bronchodilators, ribavirin, corticosteroids, immune globulin, interferon alfa and vitamin A. We enrolled 34 infants who were hospitalized for bronchiolitis to evaluate the efficacy of two different bronchodilators. Thirty-four infants under two years of age were randomized to receive either nebulized salbutamol (Group I) or nebulized ipratropium bromide (Group II). Clinical severity was scored on admission and 12-hour intervals after the start of nebulization. The symptom score evaluated five items: respiratory rate, presence of wheezing, presence of retraction, presence of nasal flaring, and general appearance. No difference was observed between the two groups in the clinical improvement on hospital admission and at the 12th, 24th, 36th and 48th hours during treatment. The mean duration of hospital stay was not significantly different between the two groups. When the groups were evaluated independently, there was a significant difference in scores before treatment and at the 48th hour of nebulization. We conclude that, ipratropium bromide and salbutamol are equally effective in the clinical recovery of bronchiolitis. Because of the side effects of salbutamol, ipratropium bromide may be primarily preferred as a bronchodilator.trinfo:eu-repo/semantics/closedAccessBronchiolitis; Bronchodilator; Ipratropium bromide; TreatmentArticle454298303Q4